Lixte Biotechnology Total Debt vs. Shares Outstanding
| LIXT Stock | USD 2.38 0.28 13.33% |
For Lixte Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lixte Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lixte Biotechnology Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lixte Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lixte Biotechnology Holdings over time as well as its relative position and ranking within its peers.
Lixte |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lixte Biotechnology. If investors know Lixte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lixte Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lixte Biotechnology is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotechnology's market value can be influenced by many factors that don't directly affect Lixte Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lixte Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Lixte Biotechnology Shares Outstanding vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Lixte Biotechnology's current stock value. Our valuation model uses many indicators to compare Lixte Biotechnology value to that of its competitors to determine the firm's financial worth. Lixte Biotechnology Holdings is rated below average in total debt category among its peers. It is rated below average in shares outstanding category among its peers creating about 7.17 of Shares Outstanding per Total Debt. Comparative valuation analysis is a catch-all technique that is used if you cannot value Lixte Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Lixte Total Debt vs. Competition
Lixte Biotechnology Holdings is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 116.76 Million. Lixte Biotechnology adds roughly 313,858 in total debt claiming only tiny portion of equities under Health Care industry.
Lixte Shares Outstanding vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Lixte Biotechnology |
| = | 313.86 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Lixte Biotechnology |
| = | 2.25 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Lixte Shares Outstanding Comparison
Lixte Biotechnology is currently under evaluation in shares outstanding category among its peers.
Lixte Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Lixte Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lixte Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Lixte Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Lixte Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was founded in 2005 and is based in Pasadena, California. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Lixte Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Lixte Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lixte Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lixte Biotechnology's important profitability drivers and their relationship over time.
Use Lixte Biotechnology in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lixte Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lixte Biotechnology will appreciate offsetting losses from the drop in the long position's value.Lixte Biotechnology Pair Trading
Lixte Biotechnology Holdings Pair Trading Analysis
The ability to find closely correlated positions to Lixte Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lixte Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lixte Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lixte Biotechnology Holdings to buy it.
The correlation of Lixte Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lixte Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lixte Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lixte Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Lixte Biotechnology position
In addition to having Lixte Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Candy and Soda Thematic Idea Now
Candy and Soda
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Candy and Soda theme has 13 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Candy and Soda Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.